Nanodropper, INC

Nanodropper manufactures an FDA-listed, volume-reducing adaptor for eyedrop bottles designed to reduce drop size by over 60%, minimizing medication waste and reducing patient costs. The device twists onto compatible eyedrop bottles and addresses a critical clinical and economic issue: standard eyedrop bottles dispense approximately five times the volume the human eye can absorb, with up to 80% of each drop wasted through overflow or tear-duct drainage. Clinical research demonstrates that smaller drops are therapeutically equivalent to standard drops while reducing systemic side effects and improving patient adherence. The Nanodropper extends medication bottle life, allowing patients to achieve 5–6 weeks of therapy from single bottles normally depleted in 2–3 weeks, resulting in significant cost savings for expensive prescription ophthalmologic medications such as glaucoma treatments (some exceeding $300 per bottle). The device is compatible with most standard eyedrop bottles in two sizes and includes patient onboarding webinars and outcome-tracking surveys to validate therapeutic efficacy and cost impact. The company has received recognition from ProPublica, the American Academy of Ophthalmology, Mayo Clinic, and the U.S. Air Force, and has published clinical data supporting efficacy and safety. Target markets include glaucoma patients, dry-eye disease patients, and ophthalmology/optometry practices seeking to improve medication access and patient compliance.